Compare Solaredge Technologies Inc (SEDG) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Solaredge Technologies Inc vs Twist Bioscience Corp — how do they compare? Solaredge Technologies Inc trades at $32.67 (market cap $2.00B), while Twist Bioscience Corp trades at $152.84 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 5× Solaredge Technologies Inc's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Solaredge Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Solaredge Technologies Inc for 34 Days and Twist Bioscience Corp for 27 Days on average.
| SEDG | TWST | |
|---|---|---|
Market Cap | $2.00B | $10.08B |
Volume | 2,739,860 | 4,229,037 |
Sector | Energy | Health |
52-Week High | $78.51 | $205.00 |
52-Week Low | $28.47 | $25.45 |
Typical Hold Time | 34 Days | 27 Days |
Enterprise Value | $1.86B | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SolarEdge Technologies (SEDG) trades at $33.16, down 2.59% with bearish technical signals and mixed fundamentals. The company shows revenue recovery to $1.18B in 2025 but continues posting significant losses with a -20.29% net margin. Recent news highlights legal investigations and AI data center initiatives, while analyst sentiment remains cautious with a $37.75 consensus target.
The outlook remains challenging with persistent profitability issues and legal overhangs, though the AI data center expansion offers long-term potential. Key risks include ongoing losses, high debt levels, and solar industry headwinds. The stock presents speculative appeal for investors betting on a turnaround, but requires careful risk assessment given the current financial strain.
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
